Precision Diagnostics in Respiratory Allergy : From Clinical Ground to Molecular Phenotyping

Overview

Why Precision Diagnostics Matter in Asthma & Respiratory Allergy?

Asthma remains one of the most frequently misdiagnosed chronic respiratory conditions in clinical practice.
A purely symptom-based approach — unanchored by objective testing — carries significant risk:
nearly 30% of physician-diagnosed asthma cases are excluded when subjected to lung function testing
and bronchial challenge. This misdiagnosis gap drives unnecessary treatment, delays in identifying true
pathology, and missed opportunities for precision biological therapies.

The framework presented here organises the diagnostic workup into four sequential layers —
from foundational screening through physiological testing, molecular biomarker profiling, and advanced
structural imaging — each adding granularity that enables targeted, phenotype-driven management.

Screening & The Misdiagnosis Gap

The 28% Misdiagnosis Reality

The foundational layer exposes a critical systemic problem: clinicians frequently rely on clinical grounds
(self-reported symptoms, medical history) rather than objective physiological evidence. Research demonstrates
that when physician-diagnosed asthma patients undergo lung function testing combined with bronchial challenge
testing, roughly 28% do not meet diagnostic criteria. This overdiagnosis leads to unnecessary prescribing of
inhaled corticosteroids and obscures alternate diagnoses (e.g., vocal cord dysfunction, dysfunctional breathing,
cardiac disease).

Type 2 (T2) Airway Inflammation

A central pathophysiological concept underpinning modern asthma therapy is Type 2 (T2) airway
inflammation — driven by cytokines IL-4, IL-5, and IL-13. These cytokines orchestrate eosinophilic
infiltration and IgE-mediated sensitisation, producing structural airway remodelling over time.
Identifying T2 endotype versus non-T2 is clinically decisive because it predicts response to targeted
biological agents.

Functional Testing: Spirometry & Bronchial Challenges

Spirometry (Pre- & Post-Bronchodilator)

Spirometry remains the first-line physiological tool for documenting reversible airflow obstruction.
A positive bronchodilator response is conventionally defined as an absolute increase in FEV₁ of
≥200 mL and ≥12% from baseline. Pre- and post-bronchodilator testing differentiates
fixed from variable obstruction, which is essential for distinguishing asthma from COPD or mixed disease.

Direct vs. Indirect Bronchial Challenges

When spirometry is inconclusive, bronchial provocation testing adds diagnostic resolution:

Tidal Breathing vs. Total Lung Capacity (TLC) Delivery

The method of inhaled agent delivery significantly affects test sensitivity. Methacholine challenges
delivered via tidal breathing produce more consistent and sensitive results than
deep-inhalation (TLC) methods, where deep inspiration itself may induce bronchodilation that attenuates
the provocative effect.

Biomarkers & Component-Resolved Diagnostics

Fractional Exhaled Nitric Oxide (FeNO)

FeNO is a non-invasive surrogate marker of eosinophilic airway inflammation, reflecting IL-13-driven
inducible nitric oxide synthase activity in airway epithelial cells. Interpretation uses validated
cut-off thresholds:

Blood Eosinophil Count (BEC)

Peripheral blood eosinophilia serves as an accessible, reproducible T2 biomarker. A BEC of
≥220 cells/µL (0.22 × 10⁹/L) supports a T2-high phenotype and predicts a positive
therapeutic response to anti-IL-5 biological agents such as mepolizumab, benralizumab, and reslizumab.
BEC should be measured at steady state (off oral corticosteroids) for accurate phenotyping.

Component-Resolved Diagnostics (CRD)

Traditional allergy testing uses whole allergen extracts, which cannot distinguish between
primary sensitisation (genuine allergy to a source) versus
cross-reactivity (IgE response to shared structural proteins such as profilins or lipid
transfer proteins). CRD resolves this ambiguity by testing specific purified molecular components:

• Ara h 2 (peanut) — marker of genuine peanut sensitisation, high risk of systemic reaction
• Bet v 1 (birch) — primary birch sensitisation, associated with oral allergy syndrome
• Phl p 5 (timothy grass) — marker of genuine grass pollen allergy

CRD findings directly influence immunotherapy candidacy, dietary counselling, and anaphylaxis risk stratification.

Multiplex Microarrays — ImmunoCAP ISAC

The ImmunoCAP ISAC platform enables simultaneous measurement of 112 allergen components
from 48–51 allergen sources using only 30 µL of serum. This is transformative for patients
with poly-sensitisation and complex, overlapping symptom profiles. Results are expressed as ISAC
Standardised Units (ISU), allowing semi-quantitative comparison across components.

Advanced Imaging & Biopsy

High-Resolution CT (HRCT) for Severe Asthma

HRCT of the thorax is indicated in severe or refractory asthma to characterise structural airway
pathology beyond the resolution of lung function testing. Key findings include:

• Bronchial wall thickening — correlates with disease duration and airway remodelling
• Bronchiectasis — may indicate allergic bronchopulmonary aspergillosis (ABPA) or neutrophilic disease
• Air trapping — evidence of small airway disease on expiratory imaging
• Mucus plugging — common in T2-high eosinophilic severe asthma

Diagnostic Bronchoscopy with BAL

In refractory or diagnostically uncertain cases, flexible bronchoscopy with
bronchoalveolar lavage (BAL) provides direct access to the lower airway milieu.
BAL differential cell counts can confirm eosinophilic (T2), neutrophilic, or paucigranulocytic
airway inflammation — the latter two being steroid-resistant phenotypes that do not benefit
from conventional or biological ICS-based therapy. BAL also identifies subacute bacterial
infections that may mimic or exacerbate asthma.

Transitioning from Standard Steroids to Targeted Biologics

The diagnostic pyramid’s ultimate purpose is to enable phenotype-matched biological therapy
for patients inadequately controlled on maximal inhaled therapy and oral corticosteroids (OCS).
Structural binding data supports OCS-to-biologic transitions in appropriately phenotyped patients,
reducing steroid-related morbidity.

The Four Diagnostic Layers at a Glance

• 1

  Foundation — Screening & The Misdiagnosis GapObjective testing mandatory before diagnosis. Type 2 inflammation (IL-4/5/13) defines the dominant actionable endotype. <50% of patients currently receive this in practice.

• 2

  Physiology — Functional TestingSpirometry (FEV₁ reversibility ≥200 mL + 12%) is first-line. Methacholine (direct, sensitive) and mannitol (indirect, specific) bronchial challenges resolve equivocal cases. Tidal breathing delivery preferred.

• 3

  Molecular — Biomarkers & CRDFeNO, BEC, and component-resolved allergen testing (including ISAC multiplex) characterise inflammatory phenotype and allergen sensitisation profile for precision biologic selection.

• 4

  Structural — Advanced Imaging & BiopsyHRCT documents bronchial wall changes and bronchiectasis in severe asthma. Bronchoscopy with BAL confirms airway inflammatory cell differentials and excludes infection in refractory cases.

Implementing Precision Diagnostics in Clinical Practice

The move from syndromic to phenotypic asthma diagnosis represents one of the most significant paradigm
shifts in respiratory medicine over the past two decades. The four-layer framework — screening,
physiology, molecular profiling, and structural characterisation — is not sequential in all cases;
rather, clinical context dictates which layers are activated and in what order.

For the majority of patients presenting with suspected asthma in primary care, objective spirometry with
bronchodilator response is sufficient. For those with severe, difficult-to-treat, or refractory disease,
systematic molecular phenotyping via FeNO, BEC, specific IgE, and CRD — combined with advanced imaging
when indicated — enables precise biologic matching that can dramatically reduce morbidity and steroid
burden.

Closing the misdiagnosis gap requires not simply better tests, but a cultural shift toward objective,
evidence-anchored diagnosis at the point of first clinical contact.